Recent advances in ocular drug delivery, with special emphasis on lipid based nanocarriers

Recent Patents on Nanotechnology

Volumn 9, Issue 2, 2015, Pages 94-105

  Sah, Abhishek K ^a   Suresh, Preeti K ^a  

^a PT RAVISHANKAR SHUKLA UNIVERSITY   (India)

Author keywords

Biodegradation; Eye; Lipid nanocarrier; Ophthalmic delivery; Patents

Indexed keywords

BIOCHEMISTRY; BIOCOMPATIBILITY; BIODEGRADATION; DRUG PRODUCTS; LIPIDS; LIPOSOMES; MEDICAL NANOTECHNOLOGY; PATENTS AND INVENTIONS; TARGETED DRUG DELIVERY;

CONTROLLED DRUG RELEASE; LIPID NANOCARRIER; NANOSTRUCTURED LIPID CARRIER (NLC); OCULAR DRUG DELIVERY; OPHTHALMIC DELIVERY; PATENTS; PHARMACOKINETIC PROFILES; SOLID LIPID NANOPARTICLE (SLN);

CONTROLLED DRUG DELIVERY;

DRUG CARRIER; LIPID; NANOPARTICLE;

CHEMISTRY; DRUG EFFECTS; EYE; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; PATENT;

ADMINISTRATION, OPHTHALMIC; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; EYE; HUMANS; LIPIDS; NANOPARTICLES; PATENTS AS TOPIC;

EID: 84940907263     PISSN: 18722105     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221050902150819151841     Document Type: Article

References (76)

1. [1] Suresh PK, Koner P, Das S. Timolol lipophilic ion-pair incorporated submicron emulsion: A potential ocular drug delivery system. Int J Res Pharm Biomed Sci 2011; 2(4): 1686-91.
2. [2] Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomed Nanotech Biol Med 2010; 6: 324-33.
3. [3] Dewangan D, Suresh PK. Nanosized emulsions as a drug carrier for ocular drug delivery: A review, JITPS 2011; 2(2): 59-75.
4. [4] Vandamme TF. Microemulsions as ocular drug delivery systems: Recent developments and future challenges. Prog Retin Eye Res 2002; 21: 15-34.
5. [5] Suresh PK, Sah AK. Nanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: Focus on current paradigms and future directions. Exp Opin Drug Deliv 2014; 11(11): 1-22.
6. [6] Kristinsson JK, Fridriksdottir H, Thorisdottir S, Sigurdardottir AM, Stefansson E, Loftsson T. Dexamethasone-cyclodextrin polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans. Invest Ophthalmol Vis Sci 1996; 37: 1199-1203.
7. [7] Das S, Suresh PK. Drug delivery to eye: Special reference to nanoparticles. Int J Drug Deliv 2010; 2: 12-21.
8. [8] Shivhare R, Pathak A, Shrivastava N, Singh C, Tiwari G, Goyal R. An update review on novel advanced ocular drug delivery system. World J Pharm Pharmaceutical Sci 2012; 1(1): 545-68.
9. [9] Haders DJ. New controlled release technologies broaden opportunities for ophthalmic therapies. Drug Del Tech 2008; 8(7): 48-53.
10. [10] Patel R. Alkaline ophthalmic suspensions. US5340572, 1994.
11. [11] Gan L, Wang J, Jiang M, Bartlett H, Ouyang D, Eperjesi F, Liu J, Gan Y. Recent advances in topical ophthalmic drug delivery with lipidbased nanocarriers. Drug Discovery Today 2013; 18(5/6): 290-7.
12. [12] Hom MM, Simmons PA. Understanding emulsion eye drop technology. Rev Optometry 2003; 140 (3): 124-6.
13. [13] Jain NK, Bhadra S, Bhadra D. In Jain NK. Pharmaceutical Product Development. New Delhi: CBS Publishers & Distributors 2006: pp. 182-220.
14. [14] Alany RG, Radesb T, Nicollc J, Tuckerb IG, Davies NM. W/o microemulsion for ocular delivery platform for ocular irritation and precorneal retention. J Contr Rel 2006; 111: 145-52.
15. [15] Aoki S, Mizote H, Minamoto A, M Suzuki, Mishima HK, Tanaka H. Systemic FK506 improved tear secretion in dry eye associated with chronic graft versus host disease. Br J Ophthalmol 2005; 89: 243-4.
16. [16] Souto EB, Doktorovovoa S, Mira GE, Egea MA, Garcia ML. Feasibility of lipid nanoparticles for ocular delivery of antiinflammatory drugs. Curr Eye Res 2010; 35(7): 537-52.
17. [17] Gasco MR, Saettone MF, Zara GP. Pharmaceutical compositions suitable for the treatment of ophthalmic diseases. US2006/0024374, 2006.
18. [18] Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002a; 242: 121-8.
19. [19] Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002b; 54: S131-55.
20. [20] Shah KA, Joshi MD, Patravale VB. Biocompatible microemulsions for fabrication of glyceryl monostearate solid lipid nanoparticles (SLN) of tretinoin. J Biomed Nanotech 2009; 5: 396-400.
21. [21] Caboi F, Lazzari P, Pani L, et al. Effect of 1-butanol on the microstructure of lecithin/water/tripalmitin system. Chem Phys Lipids 2005; 135: 147-56.
22. [22] Joana A, Sasha N, Maria A, Egea E. Soutoc ML. Garciaa. Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Coll Surf B: Bioint 2011; 88: 150-7.
23. [23] Luo Q, Zhao J, Zhang X, Pan W. Nanostructured lipid carrier (NLC) coated with chitosan oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 2011; 403: 185-91.
24. [24] Shen J, Deng Y, Jin X, Ping Q, Su Z, Li L. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution. Int J Pharm 2010; 402(1-2): 248-53.
25. [25] Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002; 238(1-2): 241-5.
26. [26] Attama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm 2008; 355(1-2): 307-13.
27. [27] Gokce EH, Sandri G, Bonferoni MC, et al. Cyclosporine A loaded SLNs: Evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm 2008; 364: 76-86.
28. [28] Souto EB, Doktorovova S, Gonzalez-Mira E, Egea MA, García ML. Feasibility of lipid nanoparticles for ocular delivery of antiinflammatory drugs. Curr Eye Res 2010; 35: 537-52.
29. [29] Li R, Jiang S, Liu D, et al. A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide. J Microencapsul 2011; 28: 134-41.
30. [30] Chetoni P, Burgalassi S, Monti D, Najarro M, Boldrini E. Liposome-encapsulated mitomycin C for the reduction of corneal healing rate and ocular toxicity. J Drug Deliv Sci Technol 2007; 17: 43-8.
31. [31] Habib FS, Fouad EA, Rhaman MSA, Fathalla D. Liposomes as an ocular delivery system of fluconazole: in vitro studies. Acta Ophthalmol 2010; 88: 901-4.
32. [32] Yan W, Chen W, Huang L. Mechanism of adjuvant activity of cationic liposome: Phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol Immunol 2007; 44(15): 3672-81.
33. [33] Cortesi R, Argnani R, Esposito E, et al. Cationic liposomes as potential carriers for ocular administration of peptides with antiherpetic activity. Int J Pharm 2006; 317: 90-100.
34. [34] Fresta M, Panico AM, Bucolo C, Giannavola C, Puglisi G. Characterization and in vivo ocular absorption of liposome-encapsulated acyclovir. J Pharm Pharmacol 1999; 51: 565-7.
35. [35] Gan L, Han S, Shen J, et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: improving preocular retention and ocular bioavailability. Int J Pharm 2010; 396: 179-87.
36. [36] Guinedi AS, Mortada ND, Mansour S, et al. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm 2005; 306: 71-82.
37. [37] Patel A, Cholkar K, Agrahari V, et al. Ocular drug delivery systems: an overview. World J Pharmacol 2013; 2(2): 47-64.
38. [38] Chopra P, Hao J, Li SK. Sustained release micellar carrier systems for iontophoretic transport of dexamethasone across human sclera. J Cont Rel 2002; 160: 96-104.
39. [39] Yamaguchi M, Yasued SI, Isowaki A, et al. Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. Int J Pharm 2005; 301: 121-8.
40. [40] Yamaguchi M, Ueda K, Isowaki A, et al. Mucoadhesive properties of chitosan-coated ophthalmic lipid emulsion containing indomethacin in tear fluid. Biol Pharm Bull 2009; 32: 1266-71.
41. [41] Muchar S, Abdulrazik M, Frucht-Pery J, Benita S. Ex-vivo permeation study of indomethacin from a submicron emulsion through albino rabbit cornea. J Contr Rel 1997; 44: 55-64.
42. [42] Taniguchi K, Yamazawa N, Itakura K, Morisaki K and Hayashi S. Partition characteristics and retention of anti-inflamatory steroids in liposomal ophthalmic preparations. Chem Pharm Bull 1987; 35: 1214-22.
43. [43] Taniguchi K, Itakura K, Yamazawa N, Morisaki K, Hayashi S, Yamada Y. Efficacy of a liposome preparation of antiinflammatory steroid as an ocular drug-delivery system. J Pharmacobiodyn 1988; 11: 39-46.
44. [44] Araújo J, Nikolic S, Egea MA, Souto EB, García ML. Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Colloids Surf B: Biointerf 2011; 88: 150-7.
45. [45] Araújo J, Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Optimization and physicochemical characterization of a triamcinolone acetonide loaded NLC for ocular antiangiogenic applications. Int J Pharm, 2010; 393(1-2): 167-75.
46. [46] Gonzalez-Mira E, Nikoli S, Calpena AC, et al. Improved and safe transcorneal delivery of flurbiprofen by NLC and NLC-based hydrogels. J Pharm Sci 2012; 101: 707-25.
47. [47] Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf B Biointerf 2010; 81(2): 412-21.
48. [48] Tian B, Luo Q, Song S, et al. Novel surface-modified nanostructured lipid carriers with partially deacetylated water-soluble chitosan for efficient ocular delivery. J Pharm Sci 2012; 101: 1040-9.
49. [49] Shen J, Wang Y, Ping Q, et al. Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J Control Release 2009; 137(3): 217-23.
50. [50] Gokce EH, Sandri G, Egrilmez S, et al. Cyclosporine A-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes. Curr Eye Res 2009; 34(11): 996-1003.
51. [51] Attama AA, Reichl S, Müller-Goymann CC. Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea. Curr Eye Res 2009; 34: 698-705.
52. [52] El-Gazayerly ON, Hikal AH, Preparation and evaluation of acetazolamide liposomes as ocular delivery systems. Int J Pharm1997; 158: 121-7.
53. [53] Han S, Shen J, Gan Y, et al. Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. Acta Pharmacol Sin 2010; 31: 990-8.
54. [54] Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm 2005; 290: 155-9.
55. [55] Tommaso CD, Bourges JL, Valamanesh Fatemeh. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies. Eur J Pharm Biopharm 2012; 81: 257-64.
56. [56] Shen J, Gan L, Zhu C, et al. Novel NSAIDs ophthalmic formulation: flurbiprofen axetil emulsion with low irritancy and improved anti-inflammation effect. Int J Pharm 2011; 412: 115-22.
57. [57] Li X, Nie SF, Kong J, Li N, Ju CY, Pan W. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm 2008; 363(1-2): 177-82.
58. [58] Liu Z, Zhang X, Wu H, Li J, Shu L, Liu R, Li L, Li N. Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo. Drug Dev Ind Pharm 2011; 37(4): 475-81.
59. [59] Sawaya, Assad S. Composition for a topical ophthalmic celar colloid liquid undergoes a liquid-gel phase transition in the eye. US9006214, 2015.
60. [60] Wei G, Lee BTK, Zhang W, Lu W, Lau JYN, Dennis SC. Ophthalmic composition, method for preparing the same, and use of the same. WO 2014153733A1, 2014.
61. [61] Mangiafico S, Aleo D, Grazia M, Saita A, Cro M. Ophthalmic compositions for the administration of liposoluble active ingredients. US20130108674A1, 2013.
62. [62] Venkatraman S, Natrajan JV, Wong T, Boey YCF. A liposomal formulation for ocular drug delivery. WO2012021107, 2012.
63. [63] Jiaying W, Strong S. Azithromycin NLC and its preparation method. CN101658493B, 2012.
64. [64] Ulrich MG, Ashim KM, Poonam RV. Topical drug delivery systems for ophthalmic use. European Patent Application no EP2440185A1, 2012.
65. [65] Shih S, Chang P, Tseng Y, Guo LSS, Hong K. Ophthalmic drug delivery system containing phospholipid and cholesterol. WO2011019410, 2011.
66. [66] Nian WU, Brian CK. Ophthalmic compositions of cyclosporine. WO2010141068 A1, 2010.
67. [67] Sturley SL, Trokel SL, Turkish AR. Utilization of artificial human lipids reconstituted as artificial tears for the stabilization application of ophthalmic therapeutics. WO2009005716 A1, 2009.
68. [68] Mercuri L. A liposomal complex of sodium carboxymethyl Beta-Glucan. WO2008010241, 2008.
69. [69] Mazzone MG, Moschetti VMC, Miano FG, Lo GLG. Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use. WO2008120249A1, 2008.
70. [70] Vanrell RH, Castillo JMBD, Ruiz EV, Torre MVDL, Martinez ITM. US0070292496A1, 2007.
71. [71] Bague S, Phillips B, Garrigue J, Rabinovich-Guilatt L, Lambert, G. US20060100288A1, 2006.
72. [72] Hofland H, Bongianmi J, Wheeler T. Ophthalmic liposome compositions and uses thereof. US Patent Application US20040224010A1, 2004.
73. [73] Echols JS, Holly FJ, Widera W. Three layer artificial tear formulation. US20040142038A1, 2004.
74. [74] Singh SK, Adams LA, Bandyopadhyay P, Hasan S, Hawley LC, Sims SM. Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems. US6696426B2, 2004.
75. [75] Rosa GM, Fabrizio SM, Paolo ZG. Pharmaceutical compositions suitable for the treatment of ophthalmic diseases. WO2004039351 A2, 2004.
76. [76] Benita S, Lambert G. Fatty acid eye nano preparations for dry eye disease. US20030108626A1, 2003.